Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 8, 2009, Pages 2318-2324

  Evans, D Gareth R ^a,c,d   Lalloo, Fiona ^a   Ashcroft, Linda ^b   Shenton, Andrew ^a   Clancy, Tara ^a   Baildam, Andrew D ^c   Brain, Anne ^c   Hopwood, Penelope ^b   Howell, Anthony ^b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DOCUMENTATION; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGE FACTORS; BREAST NEOPLASMS; ENGLAND; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS; TIME;

EID: 68949119494     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0171     Document Type: Article

References (38)

1. Evans DG, Gaarenstroom KN, Stirling D, et al. Screeni ng for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2008.[Epub ahead of print].
2. Hartmann LC, Schaid DJ, Woods JE, et al.Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med 1999;340:77-84.
3. Meijers-Heijboer EJ, van Geel B, van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
4. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risks in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:1055-62.
5. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Reduction in cancer risk after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. N Engl J Med 2002;346:1616-22.
6. Evans DGR, Baildam A, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet 2009;46:254-8.
7. Julian-Reynier C, Bouchard L, Evans G, et al.W omen's attitudes toward preventive strategies for hereditary breast/ovarian cancer risk differ from one country to another: differences between Manchester (UK), Marseilles (F) and Montreal (Ca). Cancer 2001;92:959-68.
8. Evans DGR, Howell A, Baildam A, et al. Risk-reduction mastectomy: clinical issues and research needs. J Natl Cancer Inst 2002;94:307.
9. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. In ternational variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008;122:2017-22.
10. Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000;31:75-80.
11. Lalloo F, Baildam A, Brain A, Hopwood P, Howell A, Evans DGR. Preventative mastectomy for women at high risk of breast cancer. Eur J Surg Oncol 2000;26:711-3.
12. McIntosh A, Shaw C, Evans G, et al. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. NICE guideline CG041. London: National Collaborating Center for Primary Care/University of Sheffield; 2004 [updated 2006]. Available from: http://www.nice.org.uk.
13. Evans DGR, Lalloo F. Risk assessment and management of high risk familial breast cancer. J Med Genet 2002;39:865-71.
14. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-14.
15. van Dijk S, Otten W, Zoeteweij MW, et al. Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment. Br J Cancer 2003;88:1675-81.
16. Byrd LM, Shenton A, Maher ER, et al. Better life expectancy in women with BRCA2 compared to BRCA1 mutations is attributable to lower frequency, later onset and better cure rates of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:1535-42.
17. Metcalfe KA, Foulkes WD, Kim-Sing C, et al. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet 2008;73:474-9.
18. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Pred ictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 1995; 24:412-9.
19. Hatcher MB, Fallowfield L, A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. Brit Med J 2001;322:76.
20. Uyei A, Peterson SK, Erlichman J, et al. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Ca ncer 2006;107:2745-51.
21. Metcalfe KA, Liede A, Hoodfar E, Scott A, Foulkes WD, Narod SA. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. J Med Genet 2000;37:866-74.
22. Phillips KA, Jenkins MA, Lindeman GJ, et al. Risk-r educing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 2006;70:198-206.
23. Foster C, Watson M, Eeles R, et al. Pr edictive genetic testing for BRCA1/2 in a UK clinical cohort: three year follow-up. Brit J Cancer 2007;96:718-24.
24. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885-92.
25. Botkin JR, Smith KR, Croyle RT, et al. Ge netic testing for a BRCA1 mutation: prophylactic surgery and screening behaviour in women 2 years post testing. Am J Med Genet 2003;118:201-9.
26. Lodder LN, Frets PG, Trijsburg RW, et al. One-year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002;73:97-112.
27. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM, et al. Presy mptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000;335:2015-20.
28. Scheuer L, Kauff N, Robson M, et al. Outcome of preventative surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-8.
29. Schwartz MD, Kaufman E, Peshkin B, et al. Bil ateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003;21:4034-41.
30. Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod SA. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005;4:97-103.
31. Julian-Reynier C, Eisinger F, Moatti J-P, Sobol H. Physician's attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 2000;8:204-8.
32. Kram V, Peretz T, Sagi M. Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. Fam Cancer 2006;5:327-35.
33. van Dijk S, van Roosmalen MS, Otten W, Stalmeier PFM. Dec ision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol 2008; 26:2358-63.
34. Metcalfe KA, Semple JL, Narod SA. Time to reconsider subcutaneous mastectomy for breast-cancer prevention? Lancet Oncol 2005;6:431-4.
35. Evans DGR, Lalloo F, Hopwood P, et al. Surgical decisions made by 160 women detected with breast cancer <50 years of age. Eur J Surg Oncol 2005;31:1112-8.
36. Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003;138:1323-8.
37. Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008;26:1093-7.
38. Evans DGR, Lalloo F, Shenton A, Boggis C, Howell A. Uptake of screening and prevention trials in women at very high risk of breast cancer. Lancet 2001;358:889-90.